← Back to patent-cliff list
NGI-226
Tier C — Watch / tradeNGI-226
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：肌腱炎
Regional status
US
Phase II
2023-06-14
EU
Phase II
2023-06-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NGI-226?
Approved indications include: 肌腱炎.
When does the NGI-226 patent expire?
No public expiry year is available for NGI-226 yet; this page updates once verified.
How do I get a quote for NGI-226 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03